Three Stocks to Sell This May as Summer Weakness Looms

As May arrives and the calendar turns toward summer, a seasonal pattern in stock market performance is reasserting itself—and according to Marc Lichtenfeld, Chief Income Strategist at the Oxford Club, three stocks deserve particular scrutiny from investors looking to reduce exposure. The analysis follows the well-documented "sell in May and go away" phenomenon, where the S&P 500 historically averages just 2% gains from May through October, compared to a robust 7% return from November through April. Against this backdrop, DexCom, Colgate-Palmolive, and Oracle face structural headwinds that make them vulnerable candidates for trimming before the summer doldrums take hold.

The case for rotating out of these three equities rests on distinct but equally compelling fundamental concerns. Each company faces either deteriorating competitive positioning, limited growth catalysts, or undisclosed financial risks that warrant closer examination by income-focused investors and growth-oriented portfolio managers alike.

Key Details: Why These Three Stocks Stand Out

DexCom ($DXCM) finds itself in an increasingly precarious competitive position despite its historical dominance in the continuous glucose monitoring market. The company faces declining growth momentum coupled with intensifying pressure from Abbott's FreeStyle Libre, which has captured significant market share in the CGM space. This competitive encroachment represents more than a cyclical challenge—it reflects a fundamental shift in the market structure where DexCom's technological advantages have narrowed. As Abbott, a larger diversified healthcare conglomerate with superior distribution channels, pushes deeper into the sector, DexCom's pricing power and market share face sustained erosion.

Colgate-Palmolive ($CL) presents a different concern entirely: the company offers investors limited upside potential combined with persistent valuation pressures. The consumer staples giant has demonstrated flat performance in recent periods while trading at valuations that offer minimal margin of safety for new entrants or existing holders seeking appreciation. In an environment where interest rates remain elevated, the company's modest growth profile and defensive characteristics fail to compensate for the opportunity cost of capital deployed elsewhere.

Perhaps most troubling is the financial architecture underlying Oracle ($ORCL). The enterprise software giant carries significant balance sheet risks that extend well beyond what most investors realize. Most notably, Oracle maintains approximately $250 billion in undisclosed lease commitments—a massive off-balance-sheet obligation that fundamentally alters the company's true leverage profile. Beyond this concern, Oracle faces projected negative free cash flow, a development that raises questions about the sustainability of its dividend and share buyback programs that have been central to its shareholder return narrative.

Market Context: Understanding the Seasonal Backdrop and Industry Dynamics

The "sell in May and go away" pattern is rooted in decades of historical market data, reflecting seasonal patterns in trading volumes, portfolio rebalancing cycles, and the traditional summer slowdown in corporate activity. While this pattern is not absolute—and certainly not a guarantee for any given year—it has proven statistically reliable over extended periods. The S&P 500's average 2% return from May through October versus 7% from November through April underscores a meaningful asymmetry that income-focused investors and risk-conscious portfolio managers have long exploited.

Within this broader seasonal context, each of the three identified stocks faces sector-specific headwinds:

• Healthcare Technology and Diagnostics: DexCom's competitive landscape has shifted dramatically as larger, better-capitalized competitors enter the space with alternative solutions. Abbott's aggressive FreeStyle Libre strategy represents an existential threat to DexCom's premium valuation multiple, which historically commanded a significant premium relative to the broader healthcare sector.

• Consumer Staples: Colgate-Palmolive exemplifies the broader challenge facing traditional consumer staples companies—mature markets, limited pricing power in many regions, and competition from both premium niche players and private-label alternatives. The sector's defensive characteristics, while valuable during recessionary periods, offer insufficient returns during periods of above-average equity market performance.

• Enterprise Software and Cloud Services: Oracle's competitive position in cloud infrastructure remains contested against formidable rivals including AWS (Amazon's cloud division), Microsoft Azure ($MSFT), and Google Cloud ($GOOGL). The company's massive lease commitments reveal a cost structure that may prove difficult to adjust should demand growth slow unexpectedly.

Investor Implications: What This Means for Portfolio Strategy

For equity investors, the recommendation to reduce exposure to these three stocks should be evaluated within the context of individual portfolio objectives and risk tolerances. However, several broader implications warrant consideration:

Valuation and Risk-Reward: All three stocks trade at valuations that fail to adequately compensate investors for the risks they face. DexCom's competitive erosion, Colgate-Palmolive's growth stagnation, and Oracle's hidden leverage represent asymmetric downside risks that may not be fully priced into current valuations.

Seasonal Rotation Opportunity: Investors utilizing seasonal timing strategies may view May as a natural inflection point to reduce defensive consumer staples positions (like $CL) and technology stocks facing structural headwinds (like $DXCM and $ORCL) in favor of more cyclically sensitive sectors that typically outperform during periods of economic expansion.

Cash Preservation: For income-focused investors, the identification of these specific sell candidates reinforces the value of maintaining elevated cash positions or short-duration fixed income during historically weak seasonal periods. The ability to redeploy capital into more attractive opportunities as summer weakness persists may prove more valuable than holding marginal positions through the seasonally weak May-October window.

Balance Sheet Transparency: Oracle's substantial undisclosed lease commitments highlight a broader concern about financial statement transparency. Investors should conduct thorough due diligence on off-balance-sheet obligations and adjusted free cash flow calculations before committing capital to any enterprise software company.

The confluence of seasonal market weakness, deteriorating fundamental positions, and elevated valuation risks makes the case for rotating out of these three stocks particularly compelling as the May trading session opens. While no investment thesis is entirely certain, and historical patterns are not guarantees of future performance, the weight of evidence suggests that risk-conscious investors should give serious consideration to reducing exposure to DexCom, Colgate-Palmolive, and Oracle as part of a disciplined portfolio management approach heading into the summer months.

For investors seeking to maintain equity exposure, the key challenge lies in identifying superior alternatives that offer better risk-adjusted return profiles while avoiding the seasonal headwinds that have historically pressured broad market indices from May through October. The identification of what to sell may ultimately prove just as valuable as identifying what to buy.